强效5-HT1A /B受体拮抗剂和5-羟色胺再摄取抑制剂SB-649915的表征:加速抗抑郁/抗焦虑疗效的临床前证据

Jeannette M. Watson, Lee A. Dawson
{"title":"强效5-HT1A /B受体拮抗剂和5-羟色胺再摄取抑制剂SB-649915的表征:加速抗抑郁/抗焦虑疗效的临床前证据","authors":"Jeannette M. Watson,&nbsp;Lee A. Dawson","doi":"10.1111/j.1527-3458.2007.00012.x","DOIUrl":null,"url":null,"abstract":"<p>An increase in brain serotonin (5-HT) levels is thought to be a key mechanism of action responsible for generating antidepressant efficacy. It has been proven that selective serotonin reuptake inhibitors are effective antidepressants, but the delay to therapeutic onset of these agents is thought to be due to the time required for 5-HT<sub>1A,</sub> and possibly 5-HT<sub>1B</sub>, autoreceptors to desensitize. Therefore, an agent incorporating 5-HT reuptake inhibition coupled with 5-HT<sub>1A</sub> and/or 5-HT<sub>1B</sub> autoreceptor antagonism may provide a fast-acting clinical agent. The current studies review the profile of SB-649915 (6-[(1-{2-[(2-methylquinolin-5-yl)oxy]ethyl}piperidin-4-yl)methyl]-2<i>H</i>-1,4-benzoxazin-3(4<i>H</i>)-one), a novel compound with high affinity for human (h) 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> receptors (pK<sub>i</sub> values of 8.6 and 8.0, respectively) as well as the (h) 5-HT transporter (SERT) (pK<sub>i</sub> value of 9.3). SB-649915 behaved as an antagonist at both 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> receptors <i>in vitro</i> and <i>in vivo,</i> reversing 5-HT, (+)8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and SKF99101-induced functional/behavioral responses. Furthermore, it inhibited [<sup>3</sup>H]5-HT reuptake in rat cortical synaptosomes, <i>in vitro</i> and <i>ex vivo</i>. In electrophysiological studies SB-649915 had no effect on rat dorsal raphe neuronal cell firing <i>per se,</i> but reversed 8-OH-DPAT–induced inhibition of firing both <i>in vitro</i> and <i>in vivo</i>. In addition, in a microdialysis study, it produced an acute increase in extracellular 5-HT in forebrain structures of the rat. Finally, SB-649915 demonstrated acute anxiolytic activity in both rodent and non-human primate and reduced the latency to onset of anxiolytic behavior, compared to paroxetine, in the rat social interaction paradigm. In summary, SB-649915 is a novel, potent 5-HT<sub>1A/1B</sub> autoreceptor antagonist, and 5-HT reuptake inhibitor. This particular pharmacological profile provides a novel mechanism that could offer fast-acting antidepressant activity.</p>","PeriodicalId":94307,"journal":{"name":"CNS drug reviews","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2007-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1527-3458.2007.00012.x","citationCount":"22","resultStr":"{\"title\":\"Characterization of the Potent 5-HT1A /B Receptor Antagonist and Serotonin Reuptake Inhibitor SB-649915: Preclinical Evidence for Hastened Onset of Antidepressant/Anxiolytic Efficacy\",\"authors\":\"Jeannette M. Watson,&nbsp;Lee A. Dawson\",\"doi\":\"10.1111/j.1527-3458.2007.00012.x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>An increase in brain serotonin (5-HT) levels is thought to be a key mechanism of action responsible for generating antidepressant efficacy. It has been proven that selective serotonin reuptake inhibitors are effective antidepressants, but the delay to therapeutic onset of these agents is thought to be due to the time required for 5-HT<sub>1A,</sub> and possibly 5-HT<sub>1B</sub>, autoreceptors to desensitize. Therefore, an agent incorporating 5-HT reuptake inhibition coupled with 5-HT<sub>1A</sub> and/or 5-HT<sub>1B</sub> autoreceptor antagonism may provide a fast-acting clinical agent. The current studies review the profile of SB-649915 (6-[(1-{2-[(2-methylquinolin-5-yl)oxy]ethyl}piperidin-4-yl)methyl]-2<i>H</i>-1,4-benzoxazin-3(4<i>H</i>)-one), a novel compound with high affinity for human (h) 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> receptors (pK<sub>i</sub> values of 8.6 and 8.0, respectively) as well as the (h) 5-HT transporter (SERT) (pK<sub>i</sub> value of 9.3). SB-649915 behaved as an antagonist at both 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> receptors <i>in vitro</i> and <i>in vivo,</i> reversing 5-HT, (+)8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and SKF99101-induced functional/behavioral responses. Furthermore, it inhibited [<sup>3</sup>H]5-HT reuptake in rat cortical synaptosomes, <i>in vitro</i> and <i>ex vivo</i>. In electrophysiological studies SB-649915 had no effect on rat dorsal raphe neuronal cell firing <i>per se,</i> but reversed 8-OH-DPAT–induced inhibition of firing both <i>in vitro</i> and <i>in vivo</i>. In addition, in a microdialysis study, it produced an acute increase in extracellular 5-HT in forebrain structures of the rat. Finally, SB-649915 demonstrated acute anxiolytic activity in both rodent and non-human primate and reduced the latency to onset of anxiolytic behavior, compared to paroxetine, in the rat social interaction paradigm. In summary, SB-649915 is a novel, potent 5-HT<sub>1A/1B</sub> autoreceptor antagonist, and 5-HT reuptake inhibitor. This particular pharmacological profile provides a novel mechanism that could offer fast-acting antidepressant activity.</p>\",\"PeriodicalId\":94307,\"journal\":{\"name\":\"CNS drug reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1111/j.1527-3458.2007.00012.x\",\"citationCount\":\"22\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CNS drug reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2007.00012.x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS drug reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2007.00012.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 22

摘要

大脑5-羟色胺(5-HT)水平的增加被认为是产生抗抑郁疗效的关键机制。选择性5-羟色胺再摄取抑制剂是有效的抗抑郁药,但这些药物的治疗延迟被认为是由于5-HT1A,可能是5-HT1B,自身受体脱敏所需的时间。因此,结合5-HT再摄取抑制与5-HT1A和/或5-HT1B自身受体拮抗剂的药物可能提供一种速效临床药物。目前的研究综述了SB-649915(6-[(1-{2-[(2-甲基喹啉-5-基)氧]乙基胡椒苷-4-基)甲基]- 2h -1,4-苯并oxazin-3(4H)-one)的谱图,这是一种对人类(h) 5-HT1A和5-HT1B受体(pKi值分别为8.6和8.0)以及(h) 5-HT转运体(SERT) (pKi值为9.3)具有高亲和力的新型化合物。SB-649915在体外和体内均可作为5-HT1A和5-HT1B受体的拮抗剂,逆转5-HT、(+)8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)和skf99101诱导的功能/行为反应。此外,在体外和离体实验中,它还能抑制大鼠皮层突触体对[3H]5-羟色胺的再摄取。在电生理研究中,SB-649915对大鼠背中缝神经元细胞本身的放电没有影响,但在体外和体内均逆转了8- oh - dpat诱导的放电抑制。此外,在一项微透析研究中,它在大鼠前脑结构中产生细胞外5-HT的急性增加。最后,与帕罗西汀相比,SB-649915在啮齿动物和非人灵长类动物中均表现出急性抗焦虑活性,并且在大鼠社会互动范式中减少了抗焦虑行为发生的潜伏期。综上所述,SB-649915是一种新型、有效的5-HT1A/1B自身受体拮抗剂和5-HT再摄取抑制剂。这种特殊的药理学特征提供了一种新的机制,可以提供快速的抗抑郁活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Characterization of the Potent 5-HT1A /B Receptor Antagonist and Serotonin Reuptake Inhibitor SB-649915: Preclinical Evidence for Hastened Onset of Antidepressant/Anxiolytic Efficacy

Characterization of the Potent 5-HT1A /B Receptor Antagonist and Serotonin Reuptake Inhibitor SB-649915: Preclinical Evidence for Hastened Onset of Antidepressant/Anxiolytic Efficacy

An increase in brain serotonin (5-HT) levels is thought to be a key mechanism of action responsible for generating antidepressant efficacy. It has been proven that selective serotonin reuptake inhibitors are effective antidepressants, but the delay to therapeutic onset of these agents is thought to be due to the time required for 5-HT1A, and possibly 5-HT1B, autoreceptors to desensitize. Therefore, an agent incorporating 5-HT reuptake inhibition coupled with 5-HT1A and/or 5-HT1B autoreceptor antagonism may provide a fast-acting clinical agent. The current studies review the profile of SB-649915 (6-[(1-{2-[(2-methylquinolin-5-yl)oxy]ethyl}piperidin-4-yl)methyl]-2H-1,4-benzoxazin-3(4H)-one), a novel compound with high affinity for human (h) 5-HT1A and 5-HT1B receptors (pKi values of 8.6 and 8.0, respectively) as well as the (h) 5-HT transporter (SERT) (pKi value of 9.3). SB-649915 behaved as an antagonist at both 5-HT1A and 5-HT1B receptors in vitro and in vivo, reversing 5-HT, (+)8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and SKF99101-induced functional/behavioral responses. Furthermore, it inhibited [3H]5-HT reuptake in rat cortical synaptosomes, in vitro and ex vivo. In electrophysiological studies SB-649915 had no effect on rat dorsal raphe neuronal cell firing per se, but reversed 8-OH-DPAT–induced inhibition of firing both in vitro and in vivo. In addition, in a microdialysis study, it produced an acute increase in extracellular 5-HT in forebrain structures of the rat. Finally, SB-649915 demonstrated acute anxiolytic activity in both rodent and non-human primate and reduced the latency to onset of anxiolytic behavior, compared to paroxetine, in the rat social interaction paradigm. In summary, SB-649915 is a novel, potent 5-HT1A/1B autoreceptor antagonist, and 5-HT reuptake inhibitor. This particular pharmacological profile provides a novel mechanism that could offer fast-acting antidepressant activity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信